Every rule your marketing answers to.

Warrant reviews your marketing against 3,388 rules from 1,267 regulators across 11 countries. Every flag is cited to its source. Search the full library below.

Coverage includes the FTC, FDA, CFPB, SEC, FINRA, NCUA, FDIC, OCC, NAIC, and regulators from all 50 U.S. states, the European Union, Canada, and more.

Get a free homepage compliance scan

Regulation guides

21 CFR 201 - Drug Labeling

21 CFR Part 201 requires OTC drug labels to carry a standardized Drug Facts panel and prescription labels to carry 'Rx only', with label claims consistent with approved labeling.

21 CFR Part 201 (incl. 201.66, 201.100); 21 U.S.C. 353(b)(4)

AK OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Alaska consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

AS 45.50.471(b)(4), (7), (12), (48); 21 C.F.R. § 201.66(c)

AL OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Alabama consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

Ala. Code 8-19-5; 21 U.S.C. 352; 21 CFR 201.66

AR OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Arkansas consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

Ark. Code § 4-88-107(a)(1), (a)(10); 21 C.F.R. § 201.66(c)

AZ OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Arizona consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

A.R.S. § 44-1522(A), (C); 21 C.F.R. § 201.66(c)

Alaska Pharmacy Advertising and Marketing Standards

Alaska's pharmacy practice law, enforced by the Alaska Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Alaska pharmacy ads.

AS 08.80.261(a)(2), (3), (9)-(11); AS 08.80.420

Arizona Pharmacy Advertising and Marketing Standards

Arizona's pharmacy practice law, enforced by the Arizona State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Arizona pharmacy ads.

A.R.S. § 32-1901.01(A)(22), (A)(26), (B)(11)

CA OTC Drug Marketing - Board of Pharmacy

California's Sherman Law bars false or misleading drug advertising; OTC drug ads must stay within the product's labeled OTC uses and must not overstate efficacy or regulatory status.

Cal. Health & Safety Code §§ 110390, 110403, 110405

CO OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Colorado consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

21 U.S.C. § 352(a); 15 U.S.C. § 52(a); 21 CFR § 201.66(c); C.R.S. § 6-1-105(1)(e)

CT OTC Drug Marketing - Dept of Consumer Protection

Connecticut's Food, Drug and Cosmetic Act and CUTPA bar false or misleading OTC drug claims; packaging must carry FDA Drug Facts labeling.

Conn. Gen. Stat. §§ 21a-106, 21a-113, 21a-114; 42-110b(a); 21 CFR § 201.66(c)

California Pharmacy Advertising and Marketing Standards

California's pharmacy practice law, enforced by the California State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in California pharmacy ads.

Cal. Bus. & Prof. Code §§ 651, 4059, 17500

Colorado Pharmacy Advertising and Marketing Standards

Colorado's pharmacy practice law, enforced by the Colorado State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Colorado pharmacy ads.

C.R.S. § 12-280-126(1)(h); C.R.S. § 12-280-123(1)(a)

Colorado Prescriber Drug Price Disclosure

Manufacturer representatives marketing a prescription drug to Colorado prescribers must provide the drug's wholesale acquisition cost and the names of up to three generic drugs in the same therapeutic class where available; only written materials can be checked.

C.R.S. § 12-280-308 (HB19-1131)

Connecticut Pharmacy Advertising and Marketing Standards

Connecticut pharmacy ads must not misstate drug efficacy or safety, call compounded drugs FDA-approved, make unqualified price claims, offer Rx incentives without federal program exclusions, or offer Rx drugs without a prescription.

Conn. Gen. Stat. §§ 21a-113, 21a-114, 42-110b(a)

Connecticut Prescriber Drug Price Disclosure

Pharmaceutical representatives marketing a legend drug to Connecticut prescribers or pharmacists are reported to be required to disclose the drug's list price in writing; the statute and any additional disclosure items need verification before the rule is enabled.

Conn. Gen. Stat. § 21a-70j(1)

DE OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Delaware consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

6 Del. C. § 2513(a); 15 U.S.C. § 52(a); 21 U.S.C. § 352(a); 21 C.F.R. § 201.66(c)

District of Columbia Pharmacy Advertising and Marketing Standards

District of Columbia pharmacy ads must not misstate drug efficacy or safety, call compounded drugs FDA-approved, make unqualified price claims, offer Rx incentives without federal program exclusions, or offer Rx drugs without a prescription.

21 U.S.C. § 352(bb); D.C. Code § 28-3904(a)(1), (a)(2), (a)(5), (a)(7), (a)(8); 42 U.S.C. § 1320a-7a(a)(5); 42 U.S.C. § 1320a-7b(b)(2)(B); 21 U.S.C. § 353(b)(1)

EU EMA Medicinal Products Advertising

Advertising prescription-only medicines to the EU general public is prohibited; unbranded disease awareness and materials for health professionals are allowed.

Directive 2001/83/EC Arts 86, 88(1)(a)

EU Medicinal Product Advertising

Public advertising of non-prescription medicines in the EU must identify the ad and the medicine, name it, invite the reader to read the leaflet, and avoid the prohibited claims in Art. 90.

Directive 2001/83/EC Arts. 87, 89(1), 90 (as amended by Directive 2004/27/EC)

FDA Center for Veterinary Medicine — Animal Drug Advertising

Animal drug ads must be truthful and balanced; prescription animal drug ads, including those aimed at owners, must present major risks and must not imply the drug is available without a veterinarian's prescription.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e); 21 CFR 201.105(b)(1)

FDA DTC Guidance - Presenting Quantitative Efficacy and Risk Information

FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.

21 U.S.C. 352(n); 21 CFR 202.1(e)(5)-(6); FDA Quantitative Efficacy and Risk DTC Guidance (2023)

FDA Direct-to-Consumer (DTC) Prescription Drug Advertising

Requires consumer TV, radio and video prescription drug ads to present the major statement of risks clearly, conspicuously and neutrally and to provide a brief summary or adequate provision.

21 CFR 202.1(e)(1) (as amended, 88 FR 80958, compliance Nov. 20, 2024)

FDA Direct-to-Consumer Prescription Drug Ads

Requires DTC Rx ads to present the major risk statement clearly, conspicuously and neutrally, to provide adequate provision for full prescribing information in broadcast, and to include a brief summary in print.

21 U.S.C. 352(n); 21 CFR 202.1(e)(1), (e)(6)

FDA Draft Guidance - Character-Space-Limited Platforms

On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e); FDA Character Space Draft Guidance (2014)

FDA Drug Labeling Requirements

Requires OTC drug labels to carry a complete Drug Facts panel in the prescribed order and format with ingredient-specific warnings.

21 CFR 201.66; 21 U.S.C. 352

FDA External Drug Products

OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.

21 CFR 358 (deemed final OTC monograph orders, FD&C Act 505G)

FDA Guidance - Communications Consistent with FDA-Required Labeling (CFL)

Data in promotion that are not in the labeling, including real-world evidence, must be consistent with the approved conditions of use and be presented with the study design, limitations and context needed to avoid misleading the reader.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(6); FDA CFL Q&A Guidance (2018)

FDA Healthcare Social Media Marketing

Social media promotion that names a prescription drug or restricted device and makes a benefit claim must present the most serious risks in the same post with balanced prominence and a link to full risk information.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e); FDA Character Space Draft Guidance (2014)

FDA Homeopathic Drug Products

Homeopathic products are drugs; marketing must not imply FDA approval, must not promote them for serious diseases, and efficacy claims must be scientifically supported or clearly qualified as based only on homeopathic theory.

21 U.S.C. 321(g)(1), 352; FDA Guidance: Homeopathic Drug Products (Dec 2022); FTC Enforcement Policy Statement on OTC Homeopathic Drug Claims (2016)

FDA Non-Compliant Prescription Drug Advertising

Rx drug ads must present risks with fair balance, include a brief summary or major statement, keep broadcast risk statements clear, conspicuous and neutral, stay within the label, and compounded-drug ads must not imply FDA approval or brand equivalence.

21 U.S.C. 352(a), (n), (bb); 21 CFR 202.1(e)(1), (e)(5), (e)(6), (e)(7)

FDA OPDP Boxed Warning Marketing Standards

Promotion of drugs with a boxed warning must convey the boxed-warning risk with prominence comparable to benefit claims, and reminder ads are not permitted for these drugs.

21 CFR 202.1(e)(1), (e)(2)(i), (e)(5)(ii), (e)(7)(viii); 21 CFR 201.57(c)(1); 21 U.S.C. 352(n)

FDA OPDP DTC Pharma Fair Balance Requirements

Prescription drug ads that name a drug and its use must present risk information with prominence comparable to benefit claims and must not overstate efficacy or safety.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(1), (e)(5)(ii), (e)(6), (e)(7)

FDA OPDP Help-Seeking / Disease Awareness Ads

Disease-awareness ads from drug firms may discuss a condition and urge a doctor visit but must not name, cue or point to a specific drug; if they do, they become product ads needing risk information.

21 CFR 202.1; 21 U.S.C. 352(n); FDA Draft Guidance, Help-Seeking and Other Disease Awareness Communications (Jan. 2004) secs. III.A, IV

FDA OPDP Off-Label Promotion Prohibition

Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.

21 U.S.C. 352(a), (f), (n); 21 CFR 202.1(e)(4)(i)(a), (e)(6)(i), (e)(6)(xi); 21 CFR 201.128; FDA SIUU Q&A Guidance (Jan. 2025) sec. V, Q2-Q5

FDA OPDP Patient Testimonial Marketing Standards

Patient testimonials for prescription drugs must not convey atypical or off-label results or downplay risk, and product-claim testimonials need risk information.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(1), (e)(4)(i)(a), (e)(5)(ii), (e)(6)

FDA OPDP Pediatric / Geriatric Pharma Marketing

Prescription drug promotion must not depict or target age groups outside the approved indication and must include labeled age-specific risks when targeting that group.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(5)(ii), (e)(6)(i), (e)(6)(xix), (e)(7)(x); 21 CFR 201.57(c)(9)(iv)-(v)

FDA OPDP Reminder Ads — No Indication Allowed

Reminder ads may name a prescription drug with limited facts but may not state or imply its use or make claims, and are not allowed for drugs with boxed warnings.

21 CFR 202.1(e)(2)(i); 21 CFR 201.100(f)

FDA OPDP Social Media Pharma Marketing

Social and character-limited posts that name a prescription drug and its benefit must state the most serious risks in the post and link to complete risk information.

21 CFR 202.1(e)(1), (e)(5)(ii), (e)(6)(i), (e)(6)(iv); 21 U.S.C. 352(a), (n)

FDA OTC Drug Labeling Requirements

OTC drug labels must carry a Drug Facts panel in the 21 CFR 201.66 format with the ingredient-specific warnings, such as the acetaminophen liver warning and aspirin Reye's syndrome warning.

21 CFR 201.66; 21 CFR 201.63, 201.314(h), 201.326

FDA OTC Drug Monograph System (Sunscreens, Acne, Antiperspirants)

Limits OTC monograph drug claims (sunscreens, acne, antiperspirants) to permitted indications and terms, bans terms such as 'sunblock' and 'waterproof', and requires Drug Facts on labeling.

21 U.S.C. 355h; 21 CFR 201.66, 201.327; former 21 CFR 333.310, 333.350, 350.50

FDA Off-Label Promotion - Digital and HCP Communication Risks

Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.

21 U.S.C. 352(a), (f); 21 CFR 202.1; FDA SIUU Q&A Guidance (Jan. 2025)

FDA Off-Label Promotion - Prohibited Practices and Safe Harbors

Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.

21 U.S.C. 331(a), 352(a)(1), 352(f); 21 CFR 201.128; 21 CFR 202.1(e)(6)(i), (xi)

FDA Prescription Drug Advertising (21 CFR 202)

Requires prescription drug advertising in all channels to present risks with fair balance, include a brief summary or equivalent, and avoid overstated, off-label or unsupported claims.

21 CFR 202.1(e); FD&C Act § 502(n)

FDA Rx DTC Broadcast - Major Statement in Clear, Conspicuous and Neutral Manner

Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.

21 CFR 202.1(e)(1); 21 U.S.C. 352(n)

FDA Rx DTC Print and Digital Ads - Brief Summary of Risks

Consumer-directed published and digital prescription drug product-claim ads must include a true statement of side effects, contraindications and effectiveness in brief summary form.

21 U.S.C. 352(n); 21 CFR 202.1(e)(1), (e)(3)(iii), (e)(5)-(6)

FDA Rx Promotion - Comparative and Uniqueness Claims

Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.

21 U.S.C. 352(a), (n), (bb); 21 CFR 202.1(e)(5), (e)(6)(ii)

FDA Rx Promotion - Fair Balance of Benefit and Risk

Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks.

21 CFR 202.1(e)(5)(ii), (e)(7)(vii)-(viii); 21 U.S.C. 352(n)

FDA Rx Promotion - Proprietary and Established Name Presentation

Wherever the proprietary name is featured, the established (generic) name must accompany it in direct conjunction, in type at least half as large and of comparable prominence.

21 CFR 202.1(b)(1)-(3); 21 CFR 201.10(g); FDA Product Name Placement Guidance (2017)

FDA Rx Promotion - Safety Claims and Risk Minimization

Promotion may not represent or suggest that a prescription drug is safer or has fewer or less serious risks than shown in its labeling, including by minimizing warnings and precautions.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(5)-(7)

FDA Rx Promotion - Use Limited to Approved Indications

Prescription drug and biologic promotion may not recommend or suggest any population, dose, regimen, timing or combination that is not in the approved labeling.

21 U.S.C. 352(a), (f), (n); 21 CFR 202.1(e)(4), (e)(5), (e)(6)

FDA Scientific Information on Unapproved Uses (SIUU) - Separation and Disclosures

Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties.

FDA SIUU Communications Q&A Guidance (Jan. 2025); 21 U.S.C. 352(a)

FDA Social Media Prescription Drug Rules

Rx drug posts by brands and paid creators must include the drug names, indication, the most serious risks and a link to full risk information, and sponsored posts need a clear material-connection disclosure under FTC rules.

21 U.S.C. 352(a), (n); 21 CFR 202.1; 16 CFR 255.5; FDA Character Space Draft Guidance (2014)

FL OTC Drug Marketing - Board of Pharmacy

Florida's Drug and Cosmetic Act bars false or misleading drug advertising; OTC drug ads must stay within labeled uses and accurately state strength and regulatory status.

Fla. Stat. ch. 499 (Florida Drug and Cosmetic Act), incl. 499.0054

FL Sunscreen Labeling Requirements

Sunscreen labels and ads in Florida must follow FDA sunscreen rules: no 'sunblock', 'waterproof' or 'sweatproof' claims, stated water-resistance times, and skin cancer claims only for broad spectrum SPF 15+ products.

21 CFR 201.327(a)(2), (c)(2)-(3), (d)(2), (e)(3)-(4), (g); Fla. Stat. § 499.007(1)

FTC Homeopathic - Efficacy Disclosure Requirements

Ads for OTC homeopathic drugs that make efficacy claims must convey that there is no scientific evidence the product works and that the claims rest only on 1700s homeopathic theories most modern experts reject.

FTC Act, 15 U.S.C. 45, 52; FTC Enforcement Policy Statement on Marketing Claims for OTC Homeopathic Drugs (2016)

FTC Homeopathic - Marketing and Presentation Standards

Homeopathic ad disclosures must be clear, conspicuous and close to the claim, and visuals or endorsements must not imply scientific or medical validation that contradicts them.

FTC Act, 15 U.S.C. 45, 52; FTC Enforcement Policy Statement on Marketing Claims for OTC Homeopathic Drugs (2016)

FTC OTC Drug Advertising - Substantiation Requirements

Efficacy, speed and comparative claims for OTC drugs require competent and reliable scientific evidence matching the strength of the claim.

FTC Act, 15 U.S.C. 45, 52; FTC Policy Statement Regarding Advertising Substantiation (1984)

Florida Pharmacy Advertising and Marketing Standards

Florida's pharmacy practice law, enforced by the Florida Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Florida pharmacy ads.

Fla. Stat. ch. 465; Fla. Admin. Code ch. 64B16

French Healthcare Advertising

French medicine ads need an ANSM visa (GP for the public, PM for health professionals); prescription-only medicines cannot be advertised to the public and claims must be on-label.

Code de la santé publique Art. L.5122-6 (al. 1 and final al.); Art. L.5122-8 (al. 1); Art. L.5122-9 (al. 1); Art. L.5122-2

GA OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Georgia consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

O.C.G.A. § 10-1-393(a), (b)(2), (b)(5), (b)(7); O.C.G.A. § 26-3-8(a)(1); 21 CFR 201.66(c)

Georgia Pharmacy Advertising and Marketing Standards

Georgia's pharmacy practice law, enforced by the Georgia Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Georgia pharmacy ads.

O.C.G.A. § 10-1-393(a), (b)(2), (b)(5), (b)(7), (b)(9)

HI OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Hawaii consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

HRS §§ 328-15(1), 328-20(a); HRS § 480-2(a); 21 CFR 201.66(c)

Hawaii Pharmacy Advertising and Marketing Standards

Hawaii's pharmacy practice law, enforced by the Hawaii Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Hawaii pharmacy ads.

Haw. Admin. R. §§ 16-95-101, 16-95-102, 16-95-103, 16-95-110(a)(13)

IA OTC Drug Marketing - Board of Pharmacy

OTC drug ads directed to Iowa consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.

15 U.S.C. § 52(a), (b); Iowa Code § 126.16(1), (2); 21 CFR 201.66(c)(4), (c)(5), (c)(6)

ID OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Idaho consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

Idaho Code § 48-603(2), (5), (7), (17); 21 CFR 201.66(c)

IL OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Illinois consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

410 ILCS 620/3.5, 15, 20; 815 ILCS 505/2; 21 CFR 201.66

IN OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Indiana consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

IC 24-5-0.5-3; 21 CFR 201.66

Idaho Pharmacy Advertising and Marketing Standards

Idaho's pharmacy practice law, enforced by the Idaho Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Idaho pharmacy ads.

Idaho Code § 48-603(2)-(3), (5), (17)

Illinois Pharmacy Advertising and Marketing Standards

Illinois pharmacy ads must not misstate drug efficacy or safety, call compounded drugs FDA-approved, make unqualified price claims, offer Rx incentives without federal program exclusions, or offer Rx drugs without a prescription.

225 ILCS 85/30(a)(29); 815 ILCS 505/2

Indiana Pharmacy Advertising and Marketing Standards

Indiana's pharmacy practice law, enforced by the Indiana State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Indiana pharmacy ads.

IC 24-5-0.5-3(a), (b)(1), (b)(2), (b)(6); 21 U.S.C. 353(b)(1); 42 U.S.C. 1320a-7a(a)(5), 1320a-7b(b); IC 25-26-13-29

Iowa Pharmacy Advertising and Marketing Standards

Iowa's pharmacy practice law, enforced by the Iowa Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Iowa pharmacy ads.

Iowa Code 155A.15(2)(b); 155A.23(1)(q); 714.16(2)(a); 21 U.S.C. 353(b)(1); 42 U.S.C. 1320a-7a(a)(5)

Italian Pharmaceutical Advertising

Italy bans public advertising of prescription medicines and requires consumer ads for non-prescription medicines to carry minimum information, a leaflet invitation and Ministry of Health authorization.

D.Lgs. 24 aprile 2006, n. 219, artt. 114-118

KS OTC Drug Marketing - State Board of Pharmacy

OTC drug marketing to Kansas consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.

K.S.A. 50-626(b)(1)(A), (F), (G), (b)(2); 21 CFR 201.66(c)

KY OTC Drug Marketing - Board of Pharmacy

OTC drug ads directed to Kentucky consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.

15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; KRS 217.105(1); KRS 217.175(5); KRS 217.065(1), (6)(a)-(b)

Kansas Pharmacy Advertising and Marketing Standards

Kansas's pharmacy practice law, enforced by the Kansas State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Kansas pharmacy ads.

K.S.A. 50-626(b); 21 U.S.C. 353(b)(1); 42 U.S.C. 1320a-7a(a)(5), 1320a-7b(b)

Kentucky Pharmacy Advertising and Marketing Standards

Kentucky's pharmacy practice law, enforced by the Kentucky Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Kentucky pharmacy ads.

KRS 315.121(2)(a), (f); 21 U.S.C. 353(b)(1); 42 U.S.C. 1320a-7a(a)(5), 1320a-7b(b)

LA OTC Drug Marketing - Board of Pharmacy

OTC drug ads directed to Louisiana consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.

15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; La. R.S. 40:625(A), (C); La. R.S. 40:617(A)(1)-(2); 21 CFR 201.66(c)(4)-(6)

Louisiana Pharmacy Advertising and Marketing Standards

Louisiana's pharmacy practice law, enforced by the Louisiana Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Louisiana pharmacy ads.

La. R.S. 37:1241(A)(19); LAC 46:LIII.1115(A); FD&C Act §§ 503A, 503B; 42 U.S.C. 1320a-7b(b); 42 U.S.C. 1320a-7a(a)(5)

MA OTC Drug Marketing - Board of Pharmacy

OTC drug ads directed to Massachusetts consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.

15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; Massachusetts state basis not verified

MD OTC Drug Marketing - State Board of Pharmacy

Maryland and federal law bar false or misleading OTC drug advertising; ads must not claim cures, FDA approval or prescription strength, or make absolute safety claims beyond the product's labeled uses.

Md. Code, Health-Gen. Title 21, Subtitle 2; Md. Code, Com. Law Sec. 13-301; 21 CFR Part 330; FTC Act Secs. 5, 12, 15

ME OTC Drug Marketing - Board of Pharmacy

OTC drug ads directed to Maine consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.

15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; 5 M.R.S. Sec. 207

MN OTC Drug Marketing - Board of Pharmacy ALT

OTC drug ads directed to Minnesota consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.

15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; Minn. Stat. § 151.36(1), (3)-(4)

MO OTC Drug Marketing - Board of Pharmacy ALT

OTC drug ads directed to Missouri consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.

15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; RSMo 196.120

MS OTC Drug Marketing - State Board of Pharmacy ALT

Mississippi and federal law bar false or misleading OTC drug ads; claims must stay within labeled symptom-relief uses without cure, absolute safety or unsupported superiority claims.

Miss. Code Ann. § 75-24-5(2); 21 C.F.R. § 201.66

MT OTC Drug Marketing - Board of Pharmacy

OTC drug ads directed to Montana consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.

15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; Mont. Code Ann. 50-31-303(1); Mont. Code Ann. 50-31-306(1)(a), (1)(f)

Maine Pharmacy Advertising and Marketing Standards

Maine's pharmacy practice law, enforced by the Maine Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Maine pharmacy ads.

32 M.R.S. Sec. 13782; 21 U.S.C. 352(a)(1); 21 U.S.C. 353a, 353b (FD&C Act Secs. 503A, 503B); 42 U.S.C. 1320a-7a(a)(5); 42 U.S.C. 1320a-7b(b); 5 M.R.S. Sec. 207

Manufacturer Copay and Savings Programs - Federal Program Beneficiary Exclusion

Manufacturer copay coupons and savings offers can implicate the federal Anti-Kickback Statute if used by Medicare, Medicaid or other government program beneficiaries, so offers must clearly exclude those beneficiaries and not target them.

42 U.S.C. 1320a-7b(b), (f); HHS-OIG Special Advisory Bulletin, Pharmaceutical Manufacturer Copayment Coupons (Sept. 2014)

Maryland Pharmacy Advertising and Marketing Standards

Maryland's pharmacy practice law, enforced by the Maryland Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Maryland pharmacy ads.

Md. Code Ann., Health Occ. Title 12

Massachusetts Pharmacy Advertising and Marketing Standards

Massachusetts pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices or efficacy, or offer copay waivers and coupons to federal health program beneficiaries.

247 CMR 9.01(9); M.G.L. c. 93A, § 2(a); 42 U.S.C. § 1320a-7a(a)(5), (i)(6)

Medicare Part D Vaccine Cost-Sharing Claims - Eligibility and Setting

Under the Inflation Reduction Act, Part D plans may not charge cost sharing for ACIP-recommended adult vaccines, so '$0 with Medicare' claims are true only for Part D or MA-PD enrollees in the recommended group, and Part D vaccines such as shingles and RSV are not Part B benefits.

42 U.S.C. 1395w-102(b)(8), (c)(5); 15 U.S.C. 45(a)(1)

Michigan Pharmacy Advertising and Marketing Standards

Michigan's pharmacy practice law, enforced by the Michigan Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Michigan pharmacy ads.

MCL 333.16221(d)(i); MCL 445.903(1); 42 U.S.C. § 1320a-7a(a)(5)

Minnesota Pharmacy Advertising and Marketing Standards

Minnesota's pharmacy practice law, enforced by the Minnesota Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Minnesota pharmacy ads.

Minn. Stat. § 151.071, subd. 2(9); 325F.67; 325D.44; 42 U.S.C. § 1320a-7a(a)(5)

Mississippi Pharmacy Advertising and Marketing Standards

Mississippi's pharmacy practice law, enforced by the Mississippi Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Mississippi pharmacy ads.

Miss. Code Ann. § 75-24-5(2); Miss. Code Ann. § 73-21-97; 42 U.S.C. § 1320a-7a(a)(5)

Missouri Pharmacy Advertising and Marketing Standards

Missouri's pharmacy practice law, enforced by the Missouri State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Missouri pharmacy ads.

Mo. Rev. Stat. § 338.055.2(14); 21 U.S.C. § 353(b)(1); 42 U.S.C. § 1320a-7b(b)

Montana Pharmacy Advertising and Marketing Standards

Montana's pharmacy practice law, enforced by the Montana Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Montana pharmacy ads.

21 U.S.C. § 353(b)(1); 42 U.S.C. § 1320a-7b(b); Mont. Code Ann. § 30-14-103

NC OTC Drug Marketing - Board of Pharmacy

OTC drug ads seen by North Carolina consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.

N.C.G.S. § 106-138; 15 U.S.C. 52, 55; 21 CFR 201.66

ND OTC Drug Marketing - State Board of Pharmacy

North Dakota and federal law bar false or misleading OTC drug ads, including implied prescription strength, cure or guarantee claims and misstated ingredients or uses.

N.D.C.C. §§ 19-02.1-02(5), 19-02.1-19; 21 CFR 201.66

NE OTC Drug Marketing - Dept of Health

OTC drug advertising to Nebraska consumers must not make deceptive cure, safety, efficacy or FDA-approval claims or promote uses beyond the label.

15 U.S.C. § 52; 21 U.S.C. § 352(a); 21 CFR 330.1(c)-(d), 201.66(c); Neb. Rev. Stat. §§ 59-1602, 87-302

NH OTC Drug Marketing - Board of Pharmacy

OTC drug ads seen by New Hampshire consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.

15 U.S.C. § 52; 21 CFR 330.1, 201.66; N.H. Rev. Stat. Ann. § 358-A:2

NJ OTC Drug Marketing - State Board of Pharmacy

New Jersey and federal law bar false or misleading OTC drug ads, including cure claims, implied prescription strength, guaranteed or instant relief and misleading endorsements.

15 U.S.C. § 52; 21 CFR 330.1, 201.66; 16 CFR 255; N.J.S.A. 56:8-2

NM OTC Drug Marketing - Board of Pharmacy

OTC drug ads seen by New Mexico consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.

NMSA 1978 § 26-1-12; 15 U.S.C. 52, 55; 21 CFR 201.66(c); 21 CFR 101.93

NV OTC Drug Marketing - State Board of Pharmacy

Nevada and federal law bar false or misleading OTC drug ads; claims must stay within labeled uses without cure, universal-age safety or absolute claims, and packaging must carry Drug Facts.

15 U.S.C. § 52; 21 CFR 330.1, 201.66; NRS 598.0915(2), (5)

NY OTC Drug Marketing - State Board of Pharmacy

New York and federal law bar false or misleading OTC drug ads, including cure, prescription-equivalence, unlabeled-use and misleading safety claims.

N.Y. Educ. Law § 6815(2); N.Y. GBL §§ 349, 350, 350-a; 15 U.S.C. 52, 55; 21 CFR 201.66

Nebraska Pharmacy Advertising and Marketing Standards

Nebraska's pharmacy practice law, enforced by the Nebraska Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Nebraska pharmacy ads.

Neb. Rev. Stat. §§ 59-1602, 87-302; 21 U.S.C. § 353(b)(1); 42 U.S.C. § 1320a-7b(b)

Nevada Pharmacy Advertising and Marketing Standards

Nevada's pharmacy practice law, enforced by the Nevada State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Nevada pharmacy ads.

NRS 639.263; NRS 639.264(1); NRS 454.221(1); NRS 598.0915(2), (3)

New Hampshire Pharmacy Advertising and Marketing Standards

New Hampshire's pharmacy practice law, enforced by the New Hampshire Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New Hampshire pharmacy ads.

N.H. Rev. Stat. Ann. § 358-A:2; 21 U.S.C. § 353(b)(1); 42 U.S.C. § 1320a-7b(b)

New Jersey Pharmacy Advertising and Marketing Standards

New Jersey's pharmacy practice law, enforced by the New Jersey Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New Jersey pharmacy ads.

N.J.S.A. 56:8-2; 21 U.S.C. § 353(b)(1); 42 U.S.C. § 1320a-7b(b)

New Mexico Pharmacy Advertising and Marketing Standards

New Mexico's pharmacy practice law, enforced by the New Mexico Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New Mexico pharmacy ads.

NMSA 1978 §61-11-1 et seq.; 16.19 NMAC

New York Pharmacy Advertising and Marketing Standards

New York's pharmacy practice law, enforced by the New York State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New York pharmacy ads.

N.Y. Educ. Law § 6810(1); N.Y. Educ. Law § 6811(12), (13); N.Y. Gen. Bus. Law § 349(a); federal: 21 U.S.C. §§ 353a, 353b (FD&C Act §§ 503A, 503B); 42 U.S.C. §§ 1320a-7b(b), 1320a-7a(a)(5)

North Carolina Pharmacy Advertising and Marketing Standards

North Carolina's pharmacy practice law, enforced by the North Carolina Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in North Carolina pharmacy ads.

N.C.G.S. §§ 106-138, 75-1.1

North Dakota Pharmacy Advertising and Marketing Standards

North Dakota's pharmacy practice law, enforced by the North Dakota State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in North Dakota pharmacy ads.

N.D.C.C. § 43-15-10(1)(b), (1)(i); federal: FD&C Act §§ 503A/503B; 42 U.S.C. §§ 1320a-7b(b), 1320a-7a(a)(5)

OH OTC Drug Marketing - State Board of Pharmacy

Ohio and federal law bar false or misleading OTC drug ads, including cure, implied prescription, off-label and guaranteed claims.

R.C. 3715.68; R.C. 1345.02(B); 15 U.S.C. 52, 55; 21 CFR 201.66

OK OTC Drug Marketing - State Board of Pharmacy

Oklahoma and federal law bar false or misleading OTC drug ads, including cure, unsourced superiority, off-label and guaranteed claims.

15 U.S.C. § 52; 21 U.S.C. § 352(a); 21 C.F.R. § 201.66

OR OTC Drug Marketing - State Board of Pharmacy

Oregon and federal law bar false or misleading OTC drug ads, including cure claims, unsourced superlatives, unsupported professional endorsements and off-label uses.

ORS 646.608; 15 U.S.C. § 52; 21 C.F.R. § 201.66

Ohio Pharmacy Advertising and Marketing Standards

Ohio's pharmacy practice law, enforced by the Ohio State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Ohio pharmacy ads.

21 U.S.C. §§ 352-353; 42 U.S.C. §§ 1320a-7a, 1320a-7b

Oklahoma Pharmacy Advertising and Marketing Standards

Oklahoma's pharmacy practice law, enforced by the Oklahoma State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Oklahoma pharmacy ads.

59 O.S. § 353 et seq.; 21 U.S.C. §§ 352-353; 42 U.S.C. §§ 1320a-7a, 1320a-7b; 15 O.S. § 753

Oregon Pharmacy Advertising and Marketing Standards

Oregon's pharmacy practice law, enforced by the Oregon State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Oregon pharmacy ads.

ORS 689.405(1)(a); OAR 855-006-0020; federal: FD&C Act §§ 503A/503B; 42 U.S.C. §§ 1320a-7b(b), 1320a-7a(a)(5)

PA OTC Drug Marketing - State Board of Pharmacy

Pennsylvania and federal law bar false or misleading OTC drug ads, including cure claims, unsourced pharmacist endorsements, absolute superlatives and off-label uses.

21 C.F.R. pt. 330; 21 C.F.R. § 201.66; 73 P.S. § 201-2(4); 15 U.S.C. § 52

Pennsylvania Pharmacy Advertising and Marketing Standards

Pennsylvania's pharmacy practice law, enforced by the Pennsylvania State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Pennsylvania pharmacy ads.

63 P.S. § 390-5(a)(9); 21 U.S.C. §§ 352, 353; 42 U.S.C. §§ 1320a-7a, 1320a-7b

RI OTC Drug Marketing - Board of Pharmacy

OTC drug ads seen by Rhode Island consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.

FTC Act Secs. 5, 12 (15 U.S.C. 45, 52); 21 U.S.C. 352; state Board of Pharmacy basis unverified

Rhode Island Pharmacy Advertising and Marketing Standards

Rhode Island's pharmacy practice law, enforced by the Rhode Island Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Rhode Island pharmacy ads.

R.I. Gen. Laws ch. 5-19.1

SC OTC Drug Marketing - Board of Pharmacy

OTC drug ads seen by South Carolina consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.

15 U.S.C. 45(a)(1), 52(a); 21 U.S.C. 352; S.C. Code § 39-23-40(a), (f); S.C. Code § 39-23-20

SD OTC Drug Marketing - State Board of Pharmacy

South Dakota and federal law bar false or misleading OTC drug ads, including cure or guarantee claims, off-label conditions, downplayed side effects and unsourced clinical claims.

SDCL § 37-24-6(1); 15 U.S.C. §§ 45, 52; 21 CFR 201.66(c)

South Carolina Pharmacy Advertising and Marketing Standards

South Carolina's pharmacy practice law, enforced by the South Carolina Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in South Carolina pharmacy ads.

S.C. Code Ann. Title 40, ch. 43

South Dakota Pharmacy Advertising and Marketing Standards

South Dakota's pharmacy practice law, enforced by the South Dakota Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in South Dakota pharmacy ads.

SDCL §§ 36-11-20(4), 37-24-6(1); 42 U.S.C. § 1320a-7a(a)(5)

TN OTC Drug Marketing - State Board of Pharmacy

Tennessee and federal law bar false or misleading OTC drug ads, including disease cure claims, risk denial, misleading ingredient comparisons and off-label efficacy claims.

Tenn. Code Ann. § 47-18-104(b); 15 U.S.C. § 52; 21 CFR 201.66

TX OTC Drug Marketing - State Board of Pharmacy

Texas and federal law bar false or misleading OTC drug ads, including disease claims, misstated ingredients, prescription-superiority claims and blanket child-safety claims; packaging must carry Drug Facts.

Tex. Bus. & Com. Code § 17.46(b)(5); Tex. Health & Safety Code § 431.021; 21 CFR 201.66

Tennessee Pharmacy Advertising and Marketing Standards

Tennessee's pharmacy practice law, enforced by the Tennessee Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Tennessee pharmacy ads.

Tenn. Code Ann. §§ 63-10-309, 47-18-104(b)

Texas Pharmacy Advertising and Marketing Standards

Texas's pharmacy practice law, enforced by the Texas State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Texas pharmacy ads.

Tex. Occ. Code § 565.001(a)

UK MHRA Human Medicines Regulations

UK law bars advertising prescription-only medicines to the public and requires medicine ads to stay on-licence, with required content for OTC ads.

Human Medicines Regulations 2012 Part 14; Sch 30

UK Medicinal Product Advertising

UK law bans advertising prescription-only medicines to the public and requires all medicine ads to match the product's authorisation, with label-reading invitations on consumer OTC ads.

Human Medicines Regulations 2012 Part 14

UT OTC Drug Marketing - State Board of Pharmacy

Utah and federal law bar false or misleading OTC drug ads, including cure claims, misleading safety or dosage statements and unsupported comparisons.

Utah Code § 58-17b-502(1)(c); 15 U.S.C. § 52; 21 C.F.R. § 201.66(c)

Utah Pharmacy Advertising and Marketing Standards

Utah pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices or efficacy, or offer copay waivers and coupons to federal health program beneficiaries.

15 U.S.C. §§ 45, 52; 42 U.S.C. § 1320a-7a(a)(5); Utah Code § 58-17b-502

VA OTC Drug Marketing - Board of Pharmacy

OTC drug advertising and labeling for Virginia consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.

15 U.S.C. §§ 45(a), 52(a); 21 U.S.C. § 352(a)(1); Va. Code § 54.1-3462(1)

VT OTC Drug Marketing - Board of Pharmacy

OTC drug advertising to Vermont consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.

15 U.S.C. § 52; 21 C.F.R. § 201.66; 9 V.S.A. § 2453

Vermont Pharmacy Advertising and Marketing Standards

Vermont's pharmacy practice law, enforced by the Vermont Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Vermont pharmacy ads.

9 V.S.A. § 2453; 15 U.S.C. § 52; 42 U.S.C. § 1320a-7a

Vermont Prescriber Drug Price Disclosure

Prescription drug marketing directed to Vermont prescribers is reported to require disclosure of the drug's price and its price relationship to other drugs in the same therapeutic class; the statute needs verification before the rule is enabled.

18 V.S.A. § 4633(a)-(b)

Virginia Pharmacy Advertising and Marketing Standards

Virginia's pharmacy practice law, enforced by the Virginia Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Virginia pharmacy ads.

21 U.S.C. §§ 352(a), 353(b)(1), 353a; 42 U.S.C. §§ 1320a-7a(a)(5), 1320a-7b(b); Va. Code § 59.1-200(A)

WA OTC Drug Marketing - State Board of Pharmacy

Washington and federal law bar false or misleading OTC drug ads, including off-label therapeutic claims, unsourced superlatives, misleading Rx comparisons and blanket safety claims.

RCW 69.04.040(5), 69.04.500, 69.04.710, 69.04.720

WI OTC Drug Marketing - Board of Pharmacy

OTC drug advertising to Wisconsin consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.

FDCA 502 (21 U.S.C. 352); FTC Act 5, 12; Wis. Stat. 100.18

WV OTC Drug Marketing - Board of Pharmacy

OTC drug advertising to West Virginia consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.

FDCA 502 (21 U.S.C. 352); FTC Act 5, 12; W. Va. Code 46A-6-104

WY OTC Drug Marketing - State Board of Pharmacy

Wyoming and federal law bar false or misleading OTC drug ads, including cure claims, misleading natural or safety claims, implied prescription efficacy and unlimited pediatric claims.

Wyo. Stat. Sec. 40-12-105; Wyo. Stat. Sec. 33-24-101 et seq.; 21 CFR Part 330; FTC Act Secs. 5, 12, 15

Washington Pharmacy Advertising and Marketing Standards

Washington pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices or efficacy, or offer copay waivers and coupons to federal health program beneficiaries.

RCW 18.64; WAC 246-945; RCW 19.86.020; 42 U.S.C. Secs. 1320a-7b(b), 1320a-7a(a)(5)

West Virginia Pharmacy Advertising and Marketing Standards

West Virginia's pharmacy practice law, enforced by the West Virginia Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in West Virginia pharmacy ads.

W. Va. Code ch. 30, art. 5

Wisconsin Pharmacy Advertising and Marketing Standards

Wisconsin pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices, efficacy or ownership, or offer copay waivers and coupons to federal health program beneficiaries.

Wis. Stat. ch. 450; Wis. Admin. Code ch. Phar; Wis. Stat. Sec. 100.18; 42 U.S.C. Secs. 1320a-7b(b), 1320a-7a(a)(5)

Browse by category

Browse by jurisdiction

Browse by regulator